Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization

Hepatology

Volumn 59, Issue 5, 2014, Pages 1864-1873

  Garlipp, Benjamin ^a   De Baere, Thierry ^b   Damm, Robert ^a   Irmscher, Romy ^a   van Buskirk, Mark ^c   Stübs, Patrick ^a   Deschamps, Frederic ^b   Meyer, Frank ^a   Seidensticker, Ricarda ^a   Mohnike, Konrad ^a   Pech, Maciej ^a   Amthauer, Holger ^a   Lippert, Hans ^a   Ricke, Jens ^a   Seidensticker, Max ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Data Reduction LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; HYPERTROPHY; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PORTAL VEIN; RETROSPECTIVE STUDIES; YTTRIUM RADIOISOTOPES;

EID: 84899492671     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26947     Document Type: Article

References (42)

1. Azoulay D, Castaing D, Krissat J, Smail A, Hargreaves GM, Lemoine A, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg 2000;232:665-672.
2. Denys A, Prior J, Bize P, Duran R, deBaere T, Halkic N, et al. Portal vein embolization: what do we know? Cardiovasc Intervent Radiol 2012;35:999-1008.
3. Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey J. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007;94:1386-1394.
4. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208-217.
5. Elias D, de Baere T, Roche A, Ducreux M, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999;86:784-788.
6. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 2001;34:267-272.
7. Hoekstra LT, van Lienden KP, Doets A, Busch ORC, Gouma DJ, van Gulik TM. Tumor progression after preoperative portal vein embolization. Ann Surg 2012;256:812-817.
8. Di Stefano DR, de Baere T, Denys A, Hakime A, Gorin G, Gillet M, et al. Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology 2005;234:625-630.
9. Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 2000;231:480-486.
10. Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012;56:464-473.
11. Wasan H, Kennedy A, Coldwell D, Sangro B, Salem R. Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases. Am J Clin Oncol 2012;35:293-301.
12. Sharma RA, Wasan HS, Love SB, Dutton S, Stokes JC, Smith JL. FOXFIRE: a phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases in patients with colorectal cancer. Clin Oncol (R Coll Radiol) 2008;20:261-263.
13. www.sirflox.com. Accessed Aug 8, 2013.
14. Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, et al. Volumetric changes after (90)Y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol 2013;20:2518-2525.
15. Fernández-Ros N, Silva N, Bilbao JI, Iñarrairaegui M, Benito A, D'Avola D, et al. Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. HPB (Oxford) 2013 [Epub ahead of print].
16. Ahmadzadehfar H, Meyer C, Ezziddin S, Sabet A, Hoff-Meyer A, Muckle M, et al. Hepatic volume changes induced by radioembolization with (90)Y resin microspheres. A single-centre study. Eur J Nucl Med Mol Imaging 2012;40:80-90.
17. Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci 2008;53:2556-2563.
18. Gulec SA, Pennington K, Hall M, Fong Y. Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol 2009;7:6.
19. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 2013;59:1029-1036.
20. de Baere T, Teriitehau C, Deschamps F, Catherine L, Rao P, Hakime A, et al. Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization. Ann Surg Oncol 2010;17:2081-2089.
21. Seidensticker R, Seidensticker M, Damm R, Mohnike K, Schütte K, Malfertheiner P, et al. Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol 2012;35:1109-1118.
22. Dezarn WA, Cessna JT, DeWerd LA, Feng W, Gates VL, Halama J, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys 2011;38:4824-4845.
23. Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013;57:1078-1087.
24. Kosiek O, Strach K, Pech M, Schulz H, Lippert H, Meyer F. Finding-specific minimally invasive approach for acute radiation-induced cholecystitis after (90)Y-radioembolisation of intrahepatic metastases. Zentralbl Chir 2013:84-87.
25. Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 2009;16:1587-1596.
26. Denys A, Lacombe C, Schneider F, Madoff DC, Doenz F, Qanadli SD, et al. Portal vein embolization with N-butyl cyanoacrylate before partial hepatectomy in patients with hepatocellular carcinoma and underlying cirrhosis or advanced fibrosis. J Vasc Interv Radiol 2005;16:1667-1674.
27. Imamura H, Shimada R, Kubota M, Matsuyama Y, Nakayama A, Miyagawa S, et al. Preoperative portal vein embolization: an audit of 84 patients. Hepatology 1999;29:1099-1105.
28. Beal IK, Anthony S, Papadopoulou A, Hutchins R, Fusai G, Begent R, et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol 2006;79:473-478.
29. Sturesson C, Keussen I, Tranberg K. Prolonged chemotherapy impairs liver regeneration after portal vein occlusion - an audit of 26 patients. Eur J Surg Oncol 2010;36:358-364.
30. Goéré D, Farges O, Leporrier J, Sauvanet A, Vilgrain V, Belghiti J. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg 2006;10:365-370.
31. Covey AM, Brown KT, Jarnagin WR, Brody LA, Schwartz L, Tuorto S, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008;247:451-455.
32. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey J. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008;15:2765-2772.
33. Simoneau E, Aljiffry M, Salman A, Abualhassan N, Cabrera T, Valenti D, et al. Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases. HPB (Oxford) 2012;14:461-468.
34. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-466.
35. Narita M, Oussoultzoglou E, Chenard M, Rosso E, Casnedi S, Pessaux P, et al. Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization. Surg Today 2011;41:7-17.
36. Kishi Y, Madoff DC, Abdalla EK, Palavecino M, Ribero D, Chun YS, et al. Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery 2008;144:744-751.
37. Nagino M, Kamiya J, Kanai M, Uesaka K, Sano T, Yamamoto H, et al. Right trisegment portal vein embolization for biliary tract carcinoma: technique and clinical utility. Surgery 2000;127:155-160.
38. Massimino KP, Kolbeck KJ, Enestvedt CK, Orloff S, Billingsley KG. Safety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomy. HPB (Oxford) 2012;14:14-19.
39. Nanashima A, Sumida Y, Shibasaki S, Takeshita H, Hidaka S, Sawai T, et al. Parameters associated with changes in liver volume in patients undergoing portal vein embolization. J Surg Res 2006;133:95-101.
40. Iñarrairaegui M, Pardo F, Bilbao JI, Rotellar F, Benito A, D'Avola D, et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol 2012;38:594-601.
41. Siddiqi NH, Devlin PM. Radiation lobectomy-a minimally invasive treatment model for liver cancer: case report. J Vasc Interv Radiol 2009;20:664-669.
42. de Graaf W, van Lienden KP, van den Esschert JW, Bennink RJ, van Gulik TM. Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg 2011;98:825-834.